Therefore, targeting GRK2 by different strategies emerges as a potentially relevant approach to treat cardiovascular disease, obesity, type 2 diabetes, or NAFLD, pathological conditions which are frequently interconnected and present as co-morbidities. This evidence concerns the gene GRK2 and metabolic dysfunction-associated steatotic liver disease.